Deutsche Bank Aktiengesellschaft Begins Coverage on Harmony Biosciences (NASDAQ:HRMY)

Deutsche Bank Aktiengesellschaft started coverage on shares of Harmony Biosciences (NASDAQ:HRMY - Free Report) in a report published on Tuesday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $55.00 target price on the stock.

HRMY has been the subject of several other reports. Needham & Company LLC reissued a "buy" rating and set a $52.00 price target on shares of Harmony Biosciences in a research report on Monday, January 13th. Cantor Fitzgerald increased their price objective on shares of Harmony Biosciences from $51.00 to $58.00 and gave the company an "overweight" rating in a research report on Wednesday, October 30th. Oppenheimer reaffirmed an "outperform" rating and issued a $59.00 price objective (up from $56.00) on shares of Harmony Biosciences in a research report on Wednesday, October 30th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $75.00 price objective on shares of Harmony Biosciences in a research report on Monday, January 27th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $55.00.

Harmony Biosciences Trading Up 0.3 %

Shares of NASDAQ HRMY traded up $0.13 during mid-day trading on Tuesday, reaching $39.21. The company had a trading volume of 246,618 shares, compared to its average volume of 540,645. The business's 50-day moving average is $35.95 and its 200-day moving average is $35.58. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. The stock has a market cap of $2.24 billion, a price-to-earnings ratio of 18.54, a price-to-earnings-growth ratio of 0.51 and a beta of 0.80. Harmony Biosciences has a 52 week low of $28.14 and a 52 week high of $41.61.

Insider Buying and Selling at Harmony Biosciences

In other news, CEO Jeffrey M. Dayno sold 19,293 shares of the business's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $40.13, for a total transaction of $774,228.09. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Sandip Kapadia sold 25,000 shares of the business's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $40.18, for a total value of $1,004,500.00. The disclosure for this sale can be found here. Insiders sold a total of 72,452 shares of company stock valued at $2,831,679 in the last three months. 30.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Harmony Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC lifted its stake in Harmony Biosciences by 92.6% during the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company's stock worth $31,000 after purchasing an additional 436 shares during the last quarter. Mendota Financial Group LLC boosted its holdings in Harmony Biosciences by 24,125.0% in the fourth quarter. Mendota Financial Group LLC now owns 969 shares of the company's stock valued at $33,000 after purchasing an additional 965 shares in the last quarter. CWM LLC boosted its holdings in Harmony Biosciences by 111.7% in the third quarter. CWM LLC now owns 1,469 shares of the company's stock valued at $59,000 after purchasing an additional 775 shares in the last quarter. KBC Group NV boosted its holdings in Harmony Biosciences by 79.9% in the fourth quarter. KBC Group NV now owns 1,844 shares of the company's stock valued at $63,000 after purchasing an additional 819 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new position in Harmony Biosciences in the third quarter valued at approximately $74,000. 86.23% of the stock is owned by institutional investors and hedge funds.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.